24.04.2013 • NewsNovartisBilanzpharmaceutical industry

Novartis Seeks Productivity Improvements with New CFO

Novartis has promoted Harry Kirsch, who has driven productivity improvements at its pharmaceuticals division, to be chief financial officer as the Swiss drugmaker looks to grow beyond a wave of patent expiries.

The surprise announcement is the second leadership change in as many quarters after Chairman Daniel Vasella stepped down in February after 17 years leading the group.

Novartis expects 2013 to be a year of transition as it bears the full brunt of last year's patent loss on its blockbuster blood pressure drug Diovan. It is counting on sales of new products, like cancer drug Afinitor, to fill the gap.

Kirsch, 48, is currently chief financial officer (CFO) of Novartis' pharmaceuticals division, which posted flat net sales in the first quarter as new products such as multiple sclerosis treatment Gilenya, up 71%, and Afinitor, up 114%, helped offset declining Diovan sales.

Novartis said on Wednesday that Kirsch, who joined Novartis ten years ago having worked as CFO at Proctor & Gamble's pharmaceutical business, had been "recognised for his ability to improve productivity."

"(Kirsch's) deep knowledge of Novartis pharmaceuticals operations and his productivity focus will now benefit the full portfolio," said Chief Executive Joseph Jimenez in a statement.

Jon Symonds, CFO for the past four years, will serve as adviser to the CEO until the end of the year, Novartis said.

First-quarter core earnings per share rose 6% to $1.32, compared with the average estimate of $1.30 in a Reuters poll of analysts, while net sales rose 2% to $14.016 billon.

The Basel-based group has forecast a mid-single digit decline in its core operating margin on a constant currency basis in 2013, as it expects competition from copycat drugs to knock up to $3.5 billion off sales.

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.